Figure 6.
The anti-hP2X7 mAb reduces clinical GVHD in humanised mice. (A) Illustration of the humanised mouse model of GVHD. NSG mice were injected with 10 × 106 hPBMCs (n = 4 donors) at Day 0 followed by 100 μg of isotype control or anti-hP2X7 (n = 14 mice for each group) mAb every second day for 8 days. Mice were monitored three times weekly for 75 days for (B) weight loss, (C) ear thickness, (D) clinical score, (E) time to GVHD onset, and (F) survival. Data represented as the mean ± SEM. (E) Symbols represent individual mice. Significance was assessed by the (B–D) two-way ANOVA with a Bonferroni post-test, (E) unpaired Student’s t-test, or (F) Mantel–Cox log-rank test for survival, with p values as shown.